N
NMRA icon

Nuveen’s Neumora Therapeutics NMRA Stock Holding History

Nuveen’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-220,970
Closed -$221K – 3356
2025
Q1 		$221K Hold
220,970
– – ﹤0.01% 3113
2024
Q4 		$2.34M Sell
220,970
-4,762
-2% -$57.1K ﹤0.01% 2317
2024
Q3 		$2.98M Hold
225,732
– – ﹤0.01% 2232
2024
Q2 		$2.22M Buy
225,732
+204,983
+988% +$2.12M ﹤0.01% 2332
2024
Q1 		$285K Hold
20,749
– – ﹤0.01% 3112
2023
Q4 		$354K Buy
+20,749
New +$255K ﹤0.01% 3109

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nuveen's NMRA Position: Q2 2025 in Review

Nuveen sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 220,970 shares — an estimated $221K sold.

Nuveen first reported a position in NMRA in Q4 2023 and held it in 6 quarters. The position peaked at $2.98M in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • Nuveen reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 220,970 Neumora Therapeutics shares in Q2 2025, an estimated $221K.
  • Nuveen first reported a position in Neumora Therapeutics in Q4 2023 and held it in 6 quarters.
  • Nuveen's Neumora Therapeutics position peaked at $2.98M in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.